Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Raw Materials: 2016-2025

Historic Raw Materials for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $8.3 million.

  • Collegium Pharmaceutical's Raw Materials rose 98.31% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 98.31%. This contributed to the annual value of $12.5 million for FY2024, which is 20.68% up from last year.
  • As of Q3 2025, Collegium Pharmaceutical's Raw Materials stood at $8.3 million, which was down 12.46% from $9.5 million recorded in Q2 2025.
  • Collegium Pharmaceutical's Raw Materials' 5-year high stood at $14.4 million during Q3 2023, with a 5-year trough of $3.7 million in Q4 2021.
  • Over the past 3 years, Collegium Pharmaceutical's median Raw Materials value was $9.3 million (recorded in 2024), while the average stood at $9.0 million.
  • In the last 5 years, Collegium Pharmaceutical's Raw Materials surged by 149.84% in 2023 and then plummeted by 70.80% in 2024.
  • Collegium Pharmaceutical's Raw Materials (Quarterly) stood at $3.7 million in 2021, then skyrocketed by 51.97% to $5.6 million in 2022, then skyrocketed by 85.43% to $10.4 million in 2023, then increased by 20.68% to $12.5 million in 2024, then spiked by 98.31% to $8.3 million in 2025.
  • Its Raw Materials was $8.3 million in Q3 2025, compared to $9.5 million in Q2 2025 and $11.8 million in Q1 2025.